A Phase II Trial of MGI-114 (NSC 683863) [6-hydroxymethylacylfulvene; irofulven] Administered as a 5-Minute Infusion Daily for Five Days Every 4 Weeks in Patients With Previously Untreated Advanced Colorectal Cancer
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 07 Feb 2013
At a glance
- Drugs Irofulven (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 07 Feb 2013 Status changed from active, no longer recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 24 Sep 2005 New trial record.